✦ LIBER ✦

28 Applying survival based cost-effectiveness analyses to estimate the impact of patent expiry on the cost-effectiveness of letrozole and anastrozole versus tamoxifen as adjuvant therapy in postmenopausal women with early breast cancer

✍ Scribed by J. Karnon; S. Kaura

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PCN116 A SURVIVAL BASED COST-EFFECTIVENE

✍ K El Ouagari; S Kaura; JD Karnon 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 82 KB

PCN32 COST-EFFECTIVENESS ANALYSIS OF LET

✍ J Karnon; TE Delea; NL Papo; V Barghout; SK Thomas; SR Johnston 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 63 KB

PCN72 COST-EFFECTIVENESS OF LETROZOLE AN

✍ J Karnon; S Kaura 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 76 KB

P181 Cost-effectiveness analysis of letr

✍ J. Karnon; M. Berli`ere; H. Depypere; L. Dirix; G. Jerusalem; P. Neven; R. Parid 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 57 KB

Cost-effectiveness analysis of anastrozo

✍ Gershon Y. Locker; Robert Mansel; David Cella; Deborah Dobrez; Sonja Sorensen; S 📂 Article 📅 2007 🏛 Springer US 🌐 English ⚖ 267 KB

PCN119 COST EFFECTIVENESS ANALYSIS OF AN

✍ N Kreif; Á Benedict; MP Lux; A Wöckel; MB Klevesath 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 92 KB